Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study-Reference-Cited by-同舟云学术

Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study

Published:2018-06 Issue:6 Volume:38 Page:628-637
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Arana Alejandro¹,Margulis Andrea V.¹,McQuay Lisa J.²,Ziemiecki Ryan²,Bartsch Jennifer L.²,Rothman Kenneth J.³,Franks Billy⁴,D'Silva Milbhor⁵,Appenteng Kwame⁵,Varas-Lorenzo Cristina¹,Perez-Gutthann Susana¹

Affiliation:

1. RTI Health Solutions; Barcelona Spain

2. RTI Health Solutions; Research Triangle Park North Carolina

3. RTI Health Solutions; Waltham Massachusetts

4. Astellas Pharma B.V.; Leiden The Netherlands

5. Astellas Pharma Global Development Inc.; Northbrook Illinois

Funder

Astellas Pharma Global Development

Publisher

Wiley

Subject

Pharmacology (medical)

Reference40 articles.

1. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society;Abrams;Urology,2003

2. Global prevalence and economic burden of urgency urinary incontinence: a systematic review;Milsom;Eur Urol,2014

3. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study;Irwin;Eur Urol,2006

4. National Institute for Health and Clinical Excellence Managing overactive bladder in women National Institute for Health and Clinical Excellence 2017 http://pathways.nice.org.uk/pathways/urinary-incontinence-in-women

5. Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology;Groen;Eur Urol,2016

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program;Pharmacoepidemiology and Drug Safety;2024-04-29

2. Patient and Clinician Challenges with Anticholinergic Step Therapy in the Treatment of Overactive Bladder: A Narrative Review;Advances in Therapy;2023-09-19

3. Anticholinergic Use for OAB in the Older Woman: An Update;Current Geriatrics Reports;2023-03-01

4. The Differential Risk of Mortality Among Users of Overactive Bladder Anticholinergic Medications and β3 Agonists;European Urology Focus;2023-01

5. CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis;Drugs - Real World Outcomes;2022-12-02